Dernières nouvelles pour Edwards Lifesciences (NYSE:EW) Stock

EDWARDS LIFESCIENCES CORP

Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and raises the price target from $80 to $85.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $85

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $75 to $81.

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $81

Edwards Lifesciences&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.
The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.49 billion</a> and within the management guidance of $1.45 billion-$1.53 billion.
Sales grew 11.9% or 10.6% adjusted, with strength <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46616916/edwards-lifesciences-reports-second-quarter-results" rel="noreferrer noopener">across all product groups</a>. Edwards Lifesciences&nbsp;reported adjusted earnings of 67 cents, beating the consensus of 62 cents and the management guidance of <a target="_blank" href="https://www.benzinga.com/25/04/44992019/edwards-lifesciences-stock-earns-analyst-upgrade-as-growth-outlook-brightens" rel="noreferrer noopener">59-65 cents per share</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/legal/25/07/46528449/court-nixes-jury-award-over-medtronics-heart-valve-infringement-claim" rel="noreferrer noopener">Court Nixes Jury Award Over Medtronic&#8217;s Heart Valve Infringement Claim</a>
The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.1 billion, marking an increase of 8.9% (or 7.8% on a constant currency basis). The company said that TAVR growth for the quarter surpassed their expectations.
Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved second-quarter sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or more than 57.1% on a constant currency basis.
In the Surgical segment, second-quarter global sales reached $267 million, an increase of 7.7% over the prior year, or 6.8% on a constant currency basis.
<h2 class="wp-block-heading">Outlook</h2>
&#8220;We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,&#8221; said Bernard Zovighian, CEO.
Edwards Lifesciences raised its 2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion compared to the consensus of $5.91 billion.
The company affirms fiscal 2025 adjusted earnings guidance of $2.40-$2.50 per share compared to the consensus of $2.48.
Edwards Lifesciences forecasts third-quarter adjusted earnings of 54-60 cents, compared to the consensus of 60 cents, and sales of&nbsp;$1.46 billion, $1.54 billion versus the consensus of $1.48 billion.
The company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for TMTT and Surgical product groups remains unchanged.
<h2 class="wp-block-heading">Analyst Insights: Goldman Sachs</h2>
Goldman Sachs said Friday that the second quarter of 2025 marked a key turning point for the company and reinforced its belief that Edwards is on track to achieve steady double-digit revenue growth again.
The firm noted that Edwards&#8217; core TAVR business is gaining momentum, even though the quarter only partially reflected the impact of the new asymptomatic indication and included just a small boost from Boston Scientific Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45655797/boston-scientific-scraps-this-aortic-valve-sticks-to-2025-outlook" rel="noreferrer noopener">planned market exit</a>. This gives Goldman confidence that the business will operate at a stronger baseline.
Analyst David Roman expects Edwards to get back to its previous strong performance over the next few years, with revenue growing over 10% and operating margins above 30%. With this kind of growth, Goldman Sachs believes the stock deserves a higher valuation, more than 30 times its earnings. The analyst maintains the Buy rating, raising the price <a target="_blank" href="https://www.benzinga.com/quote/EW/analyst-ratings" rel="noreferrer noopener">forecast from $89 to $101</a>.
<h2 class="wp-block-heading">Other Analysts</h2>
Several leading financial analysts re-evaluated their outlook on Edwards Lifesciences, with a general trend toward increased price forecasts.
Baird has maintained a Neutral rating on the company, slightly increasing its price forecast from $78 to $79. Deutsche Bank, on the other hand, reiterates a Buy rating and has significantly raised its price forecast from $85 to $94.
Evercore ISI affirms an In-Line rating, with a modest increase in its price forecast from $77 to $80. Wells Fargo continues to maintain an Overweight rating, raising its price forecast from $80 to $84.
Similarly, RBC Capital maintains an Outperform rating, lifting its price forecast from $85 to $89. Piper Sandler also keeps an Overweight rating, increasing its price target from $83 to $90.
Barclays maintains an Overweight rating and has raised its price forecast from $90 to $95. Finally, a Stifel analyst has reiterated a Buy rating, also increasing the price forecast from $90 to $95.
Price Action: EW stock is trading higher by 4.87% to $79.49 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46631878/mara-holdings-stock-slips-on-1-billion-note-offering-analyst-upgrade-offers-support" target="_blank" rel="noreferrer noopener">MARA Holdings Stock Slips On $1 Billion Note Offering, Analyst Upgrade Offers Support</a></li>
</ul>
Image via Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

Wall Street looked set to close the week on a high note, with large-cap benchmarks pushing higher in Friday's midday trading as optimism over corporate earnings and progress on global trade talks provided support for risk assets. The S&amp;P 500 climbed 0.4% to 6,390, marking a fresh all-time high and the Nasdaq 100 also rose 0.5% to break above 23,330, led by strength in <a href="https://www.benzinga.com/topic/technology-stocks">tech and consumer names. </a>
<ul class="wp-block-list">
<li>QQQ ETF has risen 40% off April&#8217;s lows. <a href="https://www.benzinga.com/quote/QQQ">Track it now here.</a> </li>
</ul>
With today's gains on Wall Street, the combined market capitalization of the Magnificent Seven has hit a new record of $19 trillion, with NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) alone climbing to $4.25 trillion.
The Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>) is up 1.4% this week and is on pace to log its seventh weekly gain in the last eight.
Markets were buoyed by news from Brussels, where European officials confirmed a Sunday meeting with President Donald Trump. Investors are anticipating the U.S. will move forward with a 15% tariff on EU goods, mirroring the Japan deal structure finalized earlier this week.
President Donald Trump indicated confidence that the Federal Reserve will begin cutting rates, just a day after his high-profile visit to Fed Chair Jerome Powell in Washington, D.C.
Yields on 10-year Treasury bonds held steady at 4.40%, unchanged for the week, while the U.S. dollar index rose 0.3%, paring weekly losses but still set to close lower.
Commodities were broadly weaker. Gold dropped 1.2% to $3,329 per ounce, silver slid 2.4% to $38 per ounce and WTI crude oil declined 1% to $65.40 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) extended its decline for a third straight session, slipping 2.2% toward $115,800 and heading for its second consecutive weekly loss—a streak not seen since March 2025.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,322.82</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,389.82</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,807.79</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,251.34</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.4% to $585.34.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.2% up to $447.87.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $567.18.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) held steady at $223.55.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1%.</li>
</ul>
<h2 class="wp-block-heading">Friday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rebounded 5.6% after sliding 8.2% on Thursday amid weaker-than-expected quarterly results. </li>
</ul>
Stocks reacting to earnings reports included:
<ul class="wp-block-list">
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) down 8.94%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) up 4.58%</li>
<li>HA Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAHC#NASDAQ">HAHC</a>) down 2.97%</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) up 5.80%</li>
<li>Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) down 0.75%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) up 0.80%</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) down 17.48%</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) up 3.63%</li>
<li>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) up 6.29%</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) down 0.99%</li>
<li>Shinhan Financial Group Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHG#NYSE">SHG</a>) up 1.26%</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) up 11.91%</li>
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46628310/booz-allen-sticks-to-bold-2026-outlook-as-backlog-hits-38-billion">Booz Allen </a>Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) down 2.27%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) up 4.90%</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) up 5.49%</li>
<li>AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) down 0.13%</li>
<li>OneMain Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) up 0.87%</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) up 2.24%</li>
<li>Gentex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) up 14.19%</li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46633129/trumps-fed-visit-powell-interest-rates">Trump&#8217;s Rare Fed Visit Sparks Talks Of A $7 Trillion Problem</a> Photo: khunkornStudio via Shutterstock<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46633129/trumps-fed-visit-powell-interest-rates"> </a></li>
</ul>

Equities

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

ETFs

$BTC

CHTR

DECK

SPDR Dow Jones Industrial Average ETF Trust

FCNCA

GNTX

HAHC

INTC

MAGS

NVDA

SAIA

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

US Stocks Hit New Highs As Magnificent Seven Reach $19 Trillion: What's Moving Markets Friday?

Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and raises the price target from $87 to $95.

Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $81 to $82.

Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $82

Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $90 to $95.

Stifel Maintains Buy on Edwards Lifesciences, Raises Price Target to $95

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and raises the price target from $90 to $95.

Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95

Piper Sandler analyst Adam Maeder maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and raises the price target from $83 to $90.

Piper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $90

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and raises the price target from $85 to $89.

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $89

Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and raises the price target from $80 to $84.

Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $84

Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/EW/earnings">results on Thursday</a>.
Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus expectations of $1.488 billion.
Edwards Lifesciences affirmed FY2025 adjusted EPS guidance of $2.40-$2.50 and raised FY2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion.
&#8220;We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,&#8221; said Bernard Zovighian, CEO. &#8220;Edwards is increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come as we help even more patients around the world.&#8221;
Edwards Lifesciences shares gained 5.1% to trade at $79.51 on Friday.
These analysts made changes to their price targets on Edwards Lifesciences following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst David Rescott maintained Edwards Lifesciences with a Neutral and raised the price target from $78 to $79.</li>
<li>Deutsche Bank analyst Pito Chickering maintained the stock with a Buy and boosted the price target from $85 to $94.</li>
<li>Evercore ISI Group analyst Vijay Kumar maintained Edwards Lifesciences with an In-Line rating and raised the price target from $77 to $80.</li>
</ul>
Considering buying EW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ew/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25095157/image-407-1024x589.png" alt="" class="wp-image-1000874" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25095157/image-407-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25095157/image-407-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25095157/image-407-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/25095157/image-407.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46599936/top-2-tech-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo via Shutterstock

Markets

Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a In-Line and raises the price target from $77 to $80.

Evercore ISI Group Maintains In-Line on Edwards Lifesciences, Raises Price Target to $80

Deutsche Bank analyst Pito Chickering maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $85 to $94.

Deutsche Bank Maintains Buy on Edwards Lifesciences, Raises Price Target to $94

WIIM

Edwards Lifesciences shares are trading higher following better-than-expected Q2 financial results and after the company raised its FY25 sales guidance. Also, Baird raised its price target on the stock from $78 to $79.

In the last three months, 6 analysts have published ratings on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Edwards Lifesciences and provided 12-month price targets. The average target is $83.67, accompanied by a high estimate of $95.00 and a low estimate of $77.00. Marking an increase of 5.68%, the current average surpasses the previous average price target of $79.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1753444850_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$77.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edwards Lifesciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Edwards Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>Unveiling the Story Behind Edwards Lifesciences</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
<h3>Breaking Down Edwards Lifesciences's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.23% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.34%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.56%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.75%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Edwards Lifesciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Edwards Lifesciences: What You Need To Know

Baird analyst David Rescott maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and raises the price target from $78 to $79.

Baird Maintains Neutral on Edwards Lifesciences, Raises Price Target to $79

Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Edwards Lifesciences Sees Q3 Adj EPS $0.54-$0.60 vs $0.60 Est; Sees Sales $1.460B-$1.540B vs $1.48B Est

Edwards Lifesciences Affirms FY2025 Adj EPS Guidance of $2.40-$2.50 vs $2.48 Est; Raises FY2025 Sales Guidance from $5.70B-$6.10B to $5.90B-$6.10B vs $5.91B Est

Comments

Edwards Lifesciences

Actualités

Dernières nouvelles pour Edwards Lifesciences (NYSE:EW) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL